Guest guest Posted January 21, 2008 Report Share Posted January 21, 2008 Is this new program a possible way to get low dose naltrexone looked at? -------------- Forwarded Message: -------------- From: " Philip Carll " <pcarll@...> " , - SJHMC " <.@...>, " Al Kirkland " <akirkland@...>, " Bill Rosenfelder " <bolts118@...>, " Carol Hunter " <hunterhi1@...>, " McMaster " <Ccweyekin@...>, " Chuck Moody (E-mail) " <cmoody5@...>, " " <cindylew@...>, " Connie Scheidt " <tmcnana@...>, " Nail " <.Nail@...>, " Debra Manning " <dkmann1488@...>, " Dorothy Turnbloom " <turnfive2@...>, " Edie Featherman " <moondollz@...>, " Kiesel " <mgcbullt1@...>, " Eldene Norton " <eldene@...>, " Foreman " <garyfore1@...>, " Jane Ward " <jward@...>, " Judie " <judiefos@...>, " Judy Heller (E-mail) " <judlux@...>, " " <jimandkaren8@...>, " Scheckel " <smileyx2@...>, " Kindra McFarland (E-mail) " <kindraMc@...>, " Lanny Lighthill " <mllighthill@...>, " Laurie Luker " <laurieluker@...>, " Lawrence Schroff " <lschroff@...>, " Lois McCaffrey " <loismccaff@aol ..com>, " Lois von Halle (E-mail) " <lvh314@...>, " Lynn Baker " <lynnbelle52@...>, " Lynn Grant " <lgrant3567@...>, " Marci Monaghan " <mmonaghan@...>, " Jewitt " <mag3@...>, " Stacey Lagneaux " <sns4you@...>, " " <srhodes@...>, " Terri Roskey " <terrir@...>, " Thais " <thaism@...>, " Brandee Wessel " <BWessel@...>, " Carl Manglona " <cmanglona@...>, " Carol Coon " <ccoon@...>, " Carolyne " <creed@...>, " Deborah Clatone " <dclatone@...>, " Valencia " <jvalencia@...>, " Feldman " <jfeldman@...>, " JoLee Levy " <jlevy@...>, " Jakpor " <ljakpor@...>, " Meg Elsroad " <melsroad@...>, " Meeks " <smeeks@...>, " Sheryl Keeme " <skeeme@...>, " Virginia " <vroberts@...>, " Ayla Dickey " <ayla.dickey@...>, " Barry A. Hendin, MD " <bhendin@...>, " Chris Foggatt " <chris.froggatt@...>, " Danie l Pasternak " <pasternakd@...>, " Nixon-Benn " <ni Subject: NMSS Research News Date: Tue, 27 Nov 2007 16:36:59 +0000 > National Multiple Sclerosis Society Launches Drug Development Initiative > FastForward Program Will Bridgethe Gap Between University Research and > Drug Development, Speeding New Treatments for People With MS > > New York, NY November 27, 2007 -- The National Multiple Sclerosis > Society today announced the creation of Fast Forward LLC, a > technology-transfer initiative aimed at translating promising laboratory > discoveries into effective new treatments for multiple sclerosis. > > Fast Forward, a wholly owned subsidiary of the National Multiple > Sclerosis Society, will identify, evaluate and partner with start-up and > existing companies to develop new therapies or repurpose existing drugs > for the treatment of multiple sclerosis. Fast Forward is currently > evaluating business proposals and plans to make initial investments in > early 2008. > > The National MS Society is one of only a handful of health-related > foundations and nonprofit organizations in recent years to create > technology-transfer programs, driven in part by the lack of progress in > drug development for certain diseases. Other examples include the Cystic > Fibrosis Foundation and the Leukemia & Lymphoma Society. > > Coetzee, executive director of Fast Forward, said some private > corporations are hesitant to invest the time and money needed to develop > MS-related treatments because the potential market is considered > relatively small. The worldwide market for MS-related therapies is > estimated at $4 billion annually, with just six drugs currently > available for people with multiple sclerosis. > > " It is our responsibility to find innovative and effective ways to fill > the gap between university knowledge and commercial treatments and to > meet our commitment to people with MS, " Coetzee said. " We won't hit > homeruns on every investment, but when we do, it will change the future > for people living with this disease. " > > Fast Forward has already secured $6 million of the $30 million it plans > to raise during the next six years to fund the investments. Fast Forward > expects revenue from the program, generated from royalty and milestone > payments achieved from the successful development and commercialization > of treatments. > > " There is no easy answer to finding treatments for MS, but the answers > are there and Fast Forward can help us find them, " said Weiner, a > neurologist at Harvard Medical School . " This is an important step in > finding better treatments for this disease. " > > Visit Fast Forward at www.fastforward.org/ > <https://app.umailemail.com/umbin/redirect.cgi?227.235.65,http://www.fas > tforward.org/> > > > > > > National Multiple Sclerosis Society Launches Drug Development Initiative FastForward Program Will Bridgethe Gap Between University Research and Drug Development, Speeding New Treatments for People With MS New York, NY November 27, 2007 -- The National Multiple Sclerosis Society today announced the creation of Fast Forward LLC, a technology-transfer initiative aimed at translating promising laboratory discoveries into effective new treatments for multiple sclerosis. Fast Forward, a wholly owned subsidiary of the National Multiple Sclerosis Society, will identify, evaluate and partner with start-up and existing companies to develop new therapies or repurpose existing drugs for the treatment of multiple sclerosis. Fast Forward is currently evaluating business proposals and plans to make initial investments in early 2008. The National MS Society is one of only a handful of health-related foundations and nonprofit organizations in recent years to create technology-transfer programs, driven in part by the lack of progress in drug development for certain diseases. Other examples include the Cystic Fibrosis Foundation and the Leukemia & Lymphoma Society. Coetzee, executive director of Fast Forward, said some private corporations are hesitant to invest the time and money needed to develop MS-related treatments because the potential market is considered relatively small. The worldwide market for MS-related therapies is estimated at $4 billion annually, with just six drugs currently available for people with multiple sclerosis. “It is our responsibility to find innovative and effective ways to fill the gap between university knowledge and commercial treatments and to meet our commitment to people with MS,” Coetzee said. “We won't hit homeruns on every investment, but when we do, it will change the future for people living with this disease.” Fast Forward has already secured $6 million of the $30 million it plans to raise during the next six years to fund the investments. Fast Forward expects revenue from the program, generated from royalty and milestone payments achieved from the successful development and commercialization of treatments. “There is no easy answer to finding treatments for MS, but the answers are there and Fast Forward can help us find them,” said Weiner, a neurologist at Harvard Medical School .. “This is an important step in finding better treatments for this disease.” Visit Fast Forward at www.fastforward.org/ Quote Link to comment Share on other sites More sharing options...
Guest guest Posted January 21, 2008 Report Share Posted January 21, 2008 > > Is this new program a possible way to get low dose naltrexone looked at? > Well, I'm not sure if it is or not, but about a year ago, I called Tim Coetzee (See below) and asked him why the NMSS had not funded research of LDN for the treatment of MS. His answer really astounded me. He said that no one had ever APPLIED for funding of such a study. He also said that there is a process and yearly deadline for applying, and if someone DID properly apply, the NMSS would help fund such a trial. Now, that was all BEFORE " Fast Forward, " so I would presume that if someone followed the procedures set forth for Fast Forward, the NMSS would work with them. Also, after the NIH awarded Dr. Jill money for her Phase II trials of LDN for the treatment of Crohn's Disease, I called them, too. They told me that if a Phase I trial of LDN for the treatment of MS were done and was successful, they would also award money for a Phase II trial.If the current trial at UCSF is successful, I expect all the above to be done. :-) > > > -------------- Forwarded Message: -------------- > From: " Philip Carll " <pcarll@...> > " , - SJHMC " <.@...>, " Al Kirkland " <akirkland@...>, " Bill Rosenfelder " <bolts118@...>, " Carol Hunter " <hunterhi1@...>, " McMaster " <Ccweyekin@...>, " Chuck Moody (E-mail) " <cmoody5@...>, " " <cindylew@...>, " Connie Scheidt " <tmcnana@...>, " Nail " <.Nail@...>, " Debra Manning " <dkmann1488@...>, " Dorothy Turnbloom " <turnfive2@...>, " Edie Featherman " <moondollz@...>, " Kiesel " <mgcbullt1@...>, " Eldene Norton " <eldene@...>, " Foreman " <garyfore1@...>, " Jane Ward " <jward@...>, " Judie " <judiefos@...>, " Judy Heller (E-mail) " <judlux@...>, " " <jimandkaren8@...>, " Scheckel " <smileyx2@...>, " Kindra McFarland (E-mail) " <kindraMc@...>, " Lanny Lighthill " <mllighthill@...>, " Laurie Luker " <laurieluker@...>, " Lawrence Schroff " <lschroff@...>, " Lois McCaffrey " <loismccaff@aol > .com>, " Lois von Halle (E-mail) " <lvh314@...>, " Lynn Baker " <lynnbelle52@...>, " Lynn Grant " <lgrant3567@...>, " Marci Monaghan " <mmonaghan@...>, " Jewitt " <mag3@...>, " Stacey Lagneaux " <sns4you@...>, " " <srhodes@...>, " Terri Roskey " <terrir@...>, " Thais " <thaism@...>, " Brandee Wessel " <BWessel@...>, " Carl Manglona " <cmanglona@...>, " Carol Coon " <ccoon@...>, " Carolyne " <creed@...>, " Deborah Clatone " <dclatone@...>, " Valencia " <jvalencia@...>, " Feldman " <jfeldman@...>, " JoLee Levy " <jlevy@...>, " Jakpor " <ljakpor@...>, " Meg Elsroad " <melsroad@...>, " Meeks " <smeeks@...>, " Sheryl Keeme " <skeeme@...>, " Virginia " <vroberts@...>, " Ayla Dickey " <ayla.dickey@...>, " Barry A. Hendin, MD " <bhendin@...>, " Foggatt " <chris.froggatt@...>, " Danie > l Pasternak " <pasternakd@...>, " Nixon-Benn " <ni > Subject: NMSS Research News > Date: Tue, 27 Nov 2007 16:36:59 +0000 > > National Multiple Sclerosis Society Launches Drug Development Initiative > > FastForward Program Will Bridgethe Gap Between University Research and > > Drug Development, Speeding New Treatments for People With MS > > > > New York, NY November 27, 2007 -- The National Multiple Sclerosis > > Society today announced the creation of Fast Forward LLC, a > > technology-transfer initiative aimed at translating promising laboratory > > discoveries into effective new treatments for multiple sclerosis. > > > > Fast Forward, a wholly owned subsidiary of the National Multiple > > Sclerosis Society, will identify, evaluate and partner with start-up and > > existing companies to develop new therapies or repurpose existing drugs > > for the treatment of multiple sclerosis. Fast Forward is currently > > evaluating business proposals and plans to make initial investments in > > early 2008. > > > > The National MS Society is one of only a handful of health- related > > foundations and nonprofit organizations in recent years to create > > technology-transfer programs, driven in part by the lack of progress in > > drug development for certain diseases. Other examples include the Cystic > > Fibrosis Foundation and the Leukemia & Lymphoma Society. > > > > Coetzee, executive director of Fast Forward, said some private > > corporations are hesitant to invest the time and money needed to develop > > MS-related treatments because the potential market is considered > > relatively small. The worldwide market for MS-related therapies is > > estimated at $4 billion annually, with just six drugs currently > > available for people with multiple sclerosis. > > > > " It is our responsibility to find innovative and effective ways to fill > > the gap between university knowledge and commercial treatments and to > > meet our commitment to people with MS, " Coetzee said. " We won't hit > > homeruns on every investment, but when we do, it will change the future > > for people living with this disease. " > > > > Fast Forward has already secured $6 million of the $30 million it plans > > to raise during the next six years to fund the investments. Fast Forward > > expects revenue from the program, generated from royalty and milestone > > payments achieved from the successful development and commercialization > > of treatments. > > > > " There is no easy answer to finding treatments for MS, but the answers > > are there and Fast Forward can help us find them, " said Weiner, a > > neurologist at Harvard Medical School . " This is an important step in > > finding better treatments for this disease. " > > > > Visit Fast Forward at www.fastforward.org/ > > <https://app.umailemail.com/umbin/redirect.cgi? 227.235.65,http://www.fas > > tforward.org/> > > > > > > > > > > > > > Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.